In a historic move, the World Health Organization has approved the first treatment specifically for malaria in infants, paving the way for its global use in the most affected areas. This decision comes as many countries face rising malaria infection rates among children. Statistics indicate that up to 18% of infants in some regions of Africa contract malaria, highlighting the urgent need for a safe and effective treatment.
The world recorded approximately 610,000 malaria-related deaths in 2024, with nearly three-quarters of these occurring among children under five in Africa. This situation underscores the serious treatment gap that has existed until now, as infants were treated with medications designed for older children, increasing the risk of dosing errors and toxic side effects.
Details of the Event
The new medication, known as Coartem Baby, offers a suitable solution, as it can be used for children weighing less than 2 kilograms. The medication comes in cherry-flavored tablets that can be dissolved in liquids, including breast milk, making it easier to administer to infants. It contains a combination of artemether and lumefantrine, both of which are effective in combating malaria parasites.
The Director-General of the organization, Tedros Adhanom Ghebreyesus, described this step as a turning point in the fight against the disease, noting that malaria has long deprived families of their children and robbed communities of their health and hope, but this reality is beginning to change. The approval of the drug under the WHO's prequalification program indicates that it meets quality, safety, and efficacy standards, allowing it to be purchased and distributed through health systems in countries with high infection rates, particularly in sub-Saharan Africa.
Background & Context
The treatment was developed in collaboration between Novartis and Medicines for Malaria Venture, as part of recent research efforts that have proven that infants are not as immune as previously thought. The developing organization confirmed that the medication will be available in endemic countries at low prices and largely on a non-profit basis, reflecting its commitment to combating malaria.
In Ghana, where the treatment has already begun to be used, a child named “Wonder” was among the first beneficiaries, receiving the medication at 12 weeks old after suffering from severe fever due to malaria, later recovering and living healthily. Doctors affirm that the availability of a dedicated and safe treatment for infants represents a qualitative leap, as dealing with these cases previously was fraught with anxiety and limited options.
Impact & Consequences
This step comes alongside other developments, such as new vaccines, advanced diagnostic tools, and mosquito protection networks, enhancing the chances of controlling the disease globally. Health experts view this achievement as a significant milestone towards reducing child mortality and may mark the beginning of a new phase in the fight against one of the world's deadliest infectious diseases.
The approval of a dedicated malaria treatment for infants reflects progress in public health and boosts hope for improving health conditions for children in endemic areas. This development could lead to a reduction in the health and social burdens faced by affected communities.
Regional Significance
Considering the health situation in the Arab region, this achievement could have a positive impact on efforts to combat infectious diseases. Children in Arab countries could benefit from this treatment, especially in areas experiencing a rise in malaria cases. This development also underscores the importance of international cooperation in public health.
In conclusion, the approval of malaria treatment for newborns represents a significant step towards improving public health and reducing child mortality, reflecting the international community's commitment to combating this deadly disease.